Home ›
Sarcoma Trials ›
NCT06981637
Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Trial Details
NCT ID NCT06981637
Phase PHASE2
Sponsor National Health Research Institutes, Taiwan
Status RECRUITING
Cancer Type Sarcoma
Interventions Pegylated liposomal doxorubicin
Locations (sample) Kaohsiung City, Taiwan|22.61626,120.31333 Kaohsiung City, Taiwan|22.61626,120.31333 Taichung, Taiwan|24.1469,120.6839 Tainan, Taiwan|22.99259,120.20507 Taipei, Taiwan|25.05306,121.52639
Key Eligibility Criteria
A histologically confirmed advanced soft tissue sarcoma. Note that subtypes typically do not use chemotherapy as standard treatment are not allowed… Patients received first-line anthracycline-based treatment for a minimum of 4 cycles and a maximum of 8 cycles. The best response after first-line anthracycline-based treatment must be either a complete response, partial response, or stable disease as defined… The best response should be attributed solely to systemic treatment and not to local therapy. All the patients must have at least one measurable tu…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →